Modern ideas about the etiology, pathogenesis and principles of treatment of endometrial hyperplasia

DOI

https://dx.doi.org/10.18565/aig.2021.8.192-199

Podzolkova N.M., Korennaya V.V.
Department of Obstetrics and Gynecology, Russian Medical Academy of Continuous Professional Education, Ministry of Health of Russia, Moscow, Russia

Endometrial hyperplasia is a complex and multifaceted problem in gynecology. The existing information on the development of endometrial hyperplasia is not sufficient and the specialists do not have a common understanding of the pathogenesis of the disease and its triggering mechanisms. At the same time, diagnostic and therapeutic approaches should be improved for a great number of women facing the problem of endometrial hyperplasia. Findings of the international and Russian scientists presented in the article reflect the current understanding of etiology, pathogenesis, diagnosis and treatment of this pathology. Progestogen therapy is pathogenetically justified and has proved to be effective. Among oral progestogens, dydrogesterone has progestogenic antiproliferative activity, an optimal safety profile and allows doctors to personalize therapy for patients with various somatic pathologies in order to control the symptoms of endometrial hyperplasia and prevent recurrence of the disease.
Conclusion. Scientific data collection and possibility of providing personalized therapy for patients with endometrial hyperplasia can help improve diagnostics as well as the management of the patients and minimize the risk of recurrence of this pathology.

endometrial hyperplasia

oral progestogens

dydrogesterone

anti-relapse therapy

Full text (in Russian)

Мutter L., Zaino R.J., Baak J.P.A., Bentley R.C., Robboy S. Benign Endometrial Hyperplasia Sequence and Endometrial Intraepithelial Neoplasia. International Journal of Gynecological Pathology. 2007; 26(2): 103-14. https://dx.doi.org/10.1097/PGP.0b013e31802e4696.
Cree I.A., White V.A., Indave B.I., Lokuhetty D. Revising the WHO classification: female genital tract tumours. Histopathology. 2020; 76(1): 151-6. https://dx.doi.org/10.1111/his.13977.
The American College of Obstetricians and Gynecologists Committee Opinion no. 631. Endometrial intraepithelial neoplasia. Obstet. Gynecol. 2015; 125(5): 1272-8. https://dx.doi.org/10.1097/01.AOG.0000465189.50026.20.
Reed S.D., Newton K.M., Clinton L., Epplein M., Garcia R., Allison K., Voigt L.F., Weiss N.S. Incidence of endometrial hyperplasia. Am J Obstet Gynecol. 2009; 200(6): 678.e1-6. https://dx.doi.org/10.1016/j.ajog.2009.02.032.
Lacey Jr. V.L., Chia V.M. Endometrial hyperplasia and the risk of progression to carcinoma. Maturitas 2009; 63(1): 39-44. https://dx.doi.org/10.1016/j.maturitas.2009.02.005.
Ткаченко Л.В., Свиридова Н.И. Гиперпластические процессы эндометрия в перименопаузе: современный взгляд на проблему. Вестник ВолГМУ. 2013; 3(47): 9-15. [Tkachenko L.V., Sviridova N.I. Hyperplastic processes of the endometrium in perimenopause: a modern view of the problem. Bulletin of VolGMU. 2013; 3(47): 9-15. (in Russian)].
Коренная В.В., Масс Е.Е., Колода Ю.А., Полетова Т.Н. Гиперпластические процессы эндометрия: новый взгляд на проблему. Эффективная фармакотерапия. Эндокринология. 2018; 3(26): 34-9. [Korennaya V.V., Mass Ye.Ye., Koloda Yu.A., Poletova T.N. Hyperplastic Endometrial Processes: the New Approach to the Problem. Endocrinology. 2018; 3(26): 34-9. (in Russian)].
Auclair M.-H., Yong P.J., Salvador S., Thurston J., Colgan T.J., Sebastianelli A. Guideline No. 392-Classification and Management of Endometrial Hyperplasia. J Obstet Gynaecol Can. 2019; 41(12): 1789-1800. https://doi.org/10.1016/j.jogc.2019.03.025.
Gallos I.D., Alazzam M., Clark T.J. et al. Management of Endometrial Hyperplasia. RCOG/BSGE Green-top Guideline No. 67. 2016; 67: 2-30. https://www.rcog.org.uk/globalassets/documents/guidelines/green-top-guide-lines/gtg_67_endometrial_hyperplasia.pdf.
Министерство здравоохранения Российской Федерации. Гиперплазия эндометрия. Клинические рекомендации РОАГ, 2021. 35 с. Доступ с сайта: https://roag-portal.ru/clinical_recommendations. [The Ministry of Health of the Russian Federation. Endometrial hyperplasia. Clinical recommendations of the RMOAG, 2021. 35 p. Access from the website: https://roag-portal.ru/clinical_recommendations. (in Russian)].
Министерство здравоохранения Российской Федерации. Аномальные маточные кровотечения. Клинические рекомендации РОАГ, 2021. 41 с. Доступ с сайта: https://roag-portal.ru/recommendations_gynecology [The Ministry of Health of the Russian Federation. Abnormal uterine bleeding. Clinical recommendations of the RMOAG, 2021. 41 p. Access from the website: https://roag-portal.ru/recommendations_gynecology (in Russian)].
El Behery M.M., Saleh H.S., Ibrahiem M.A., Kamal E.M., Kassem G.A., El Sayed Mohamed M. Levonorgestrel-releasing intrauterine device versus dydrogesterone for management of endometrial hyperplasia without atypia. Reprod Sci. 2015; 22(3): 329-34. https://dx.doi.org/10.1177/1933719114542014.
Максудова Н.М., Исматова М.И., Нурханова Н.О. Коррекция гиперплазии эндометрия у пациенток фертильного возраста c метаболическими нарушениями. Непрерывное медицинское образование и наука. 2015; 10(3): 15-7. [Maksudova N.M., Ismatova M.I., Nurkhanova N.O. Endometrial hyperplasia correction in reproductive age patients with metabolic disorders. Continuing medical education and science. 2015; 10(3): 15-7. (in Russian)].
Su C. Reverse of Endometrial Atypical Hyperplasia and Early endometrial carcinoma in PCOS women by Dydrogesterone plus Metformin: a pilot study. Материалы 18-го Всемирного Конгресса «Гинекологическая эндокринология», Флоренция, Италия, 7-10 марта 2018 г.
Ульрих Е.А., Кутушева Г.Ф., Урманчеева А.Ф. Дюфастон (дидрогестерон) в лечении дисфункциональных маточных кровотечений, ассоциированных с железистой гиперплазией эндометрия. Журнал акушерства и женских болезней. 2003; 52(3): 60-3. [Ulrikh E.A., Kutusheva G.F., Urmancheeva A.F. Dufaston (degidrosteron) in treatment of dysfunctional womb bleeding associated with ferrum hyperplasia of endometrium. Journal of Obstetrics and Women's Diseases. 2003; 52(3): 60-3. (in Russian)].
Соловьева А.В., Чегус Л.А. Аномальные маточные кровотечения у женщин в репродуктивном возрасте и пременопаузе. Акушерство и гинекология. 2020; 8: 29-38. [Solovyeva A.V., Chegus L.A. Abnormal uterine bleeding in women of reproductive age and premenopause. Obstetrics and Gynecology. 2020; 8: 29-38. (in Russian)]. https://dx.doi.org/10.18565/aig.2020.8.29-38
Соловьева А.В., Ермоленко К.С. Дифференцированный подход к выбору терапии у женщин с аномальными маточными кровотечениями. Акушерство и гинекология. 2018; 3: 157-60. [Solovyeva A.V., Ermolenko K.S. A differentiated approach to the choice of therapy in women with abnormal uterine bleeding. Obstetrics and gynecology. 2018; 3: 157-60. (in Russian)]. https://dx.doi.org/10.18565/aig.2018.3.157-160.
Дубровина С.О., Киревнина Л.В., Лесной М.Н. Аномальное маточное кровотечение: причины, диагностика и лечение. Акушерство и гинекология. 2021; 1: 170-7. [Dubrovina S.O., Kirevnina L.V., Lesnoy M.N. Abnormal uterine bleeding: causes, diagnosis, and treatment. Obstetrics and gynecology. 2021; 1: 170-7. (in Russian)]. https://dx.doi.org/10.18565/aig.2021.1.170-177.
Дубровина С.О. Рациональный подход к гормональной терапии у женщин старше 40 лет. Акушерство и гинекология. 2019; 7: 112-6. [Dubrovina S.O. Rational approach to hormonal therapy among women after 40 years. Obstetrics and gynecology. 2019; 7: 112-6. (in Russian)]. https://dx.doi.org/10.18565/aig.2019.7.112-116.
Подзолкова Н.М., Татарчук Т.Ф., Дощанова А.М., Ешимбетова Г.З., Сумятина Л.В. Нормализация менструального цикла дидрогестероном. Акушерство и гинекология. 2018; 6: 70-6. [Podzolkova N.M., Tatarchuk T.F., Doshchanova A.M., Eshimbetova G., Sumyatina L.V. Menstrual cycle normalization with dydrogesterone. Obstetrics and gynecology. 2018; 6: 70-6. (in Russian)]. https://dx.doi.org/10.18565/aig.2018.6.70-76
Podzolkova N., Tatarchuk T., Doshchanova A., Eshimbetova G., Pexman-Fieth C. Dydrogesterone treatment for menstrual-cycle regularization in routine clinical practice: a multicenter observational study. Gynecol Endocrinol. 2016; 32(3): 246-9. https://dx.doi.org/10.3109/09513590.2015.1115832.
Trivedi N., Chauhan N., Vaidya V. Effectiveness and safety of dydrogesterone in regularization of menstrual cycle: a post-marketing study. Gynecol Endocrinol. 2016; 32(8): 667-71. https://dx.doi.org/10.3109/09513590.2016.1152238.
Tajjamal A., Zaman F. Severity of bleeding is a predictor of quality of life in women with heavy menstrual bleeding under dydrogesterone treatment in a prospective, multicentre, observational study. Gazzetta Medica Italiana Archivio per le Scienze Mediche. 2015; 174(9): 391-8.
Beniuk V.O., Ginzburg V.H., Govsieiev D.O., Oleshko V.F., Kovaliuk T.V., Kravchenko Y.V., Luchko A.S. New approaches to prophylaxis of endometrium hyperplasia relaps in premenopausal women. Reproductive Endocrinology. 2021; 58: 63-72. https://doi.org/10.18370/2309-4117.2021.58.63-72
Guidelines on Clinical Management of Endometrial Hyperplasia. HKCOG Gudelines Number 16 (September 2015).
Gadducci A., Spirito N., Baroni E., Tana R., Genazzani A.R. The fertility-sparing treatment in patients with endometrial atypical hyperplasia and early endometrial cancer: a debated therapeutic option.Gynecol Endocrinol. 2009; 25(10): 683-91. https://dx.doi.org/10.1080/09513590902733733.
Klip H., Burger C.W., van Leeuwen F.E. Risk of hormone-related cancers after ovarian stimulation for in-vitro fertilisation in a cohort of 25,152 women. In: Klip H. (ed). Long Term Health Effects of Subfertility Treatment. Ipskamp BV, Enschede, The Netherlands: Print Partners; 2002. p. 55-82.
Russo M., Newell J.M., Budurlean L., Houser K.R., Sheldon K., Kesterson J. et al. Mutational profile of endometrial hyperplasia and risk of progression to endometrioid adenocarcinoma. Cancer. 2020; 126(12): 2775-83. https://dx.doi.org/10.1002/cncr.32822.
Multinu F., Chen J., Madison J.D., Torres M., Casarin J., Visscher D., Shridhar V. et al. Analysis of DNA methylation in endometrial biopsies to predict risk of endometrial cancer. Gynecol. Oncol. 2020; 156(3): 682-8. https://dx.doi.org/10.1016/j.ygyno.2019.12.023.

Received 16.08.2021

Accepted 20.08.2021

Natalia M. Podzolkova, Dr. Med. Sci., Professor, Head of the Department of Obstetrics and Gynecology, Russian Medical Academy of Continuous Professional Education, Ministry of Health of Russia. Tel.: +7(499)252-21-04. E-mail: podzolkova@gmail.com. 125993, Russia, Moscow, Barrikadnaya str., 2/1, build. 1.
Vera V. Korennaya, PhD, Associate Professor of the Department of Obstetrics and Gynecology, Russian Medical Academy of Continuous Professional Education,
Ministry of Health of Russia. Tel.: +7(499)252-21-04. E-mail: drkorennaya@mail.ru. 125993, Russia, Moscow, Barrikadnaya str., 2/1, build. 1.

For citation: Podzolkova N.M., Korennaya V.V. Modern ideas about the etiology, thogenesis and principles of treatment of endometrial hyperplasia.
Akusherstvo i Ginekologiya / Obstetrics and gynecology. 2021; 8: 192-199
https://dx.doi.org/10.18565/aig.2021.8.192-199

Modern ideas about the etiology, pathogenesis and principles of treatment of endometrial hyperplasia

Podzolkova N.M., Korennaya V.V.

Keywords

References

About the Authors

Similar Articles